JP2015505823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505823A5 JP2015505823A5 JP2014543617A JP2014543617A JP2015505823A5 JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5 JP 2014543617 A JP2014543617 A JP 2014543617A JP 2014543617 A JP2014543617 A JP 2014543617A JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- variant
- polypeptide
- pharmaceutical composition
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564602P | 2011-11-29 | 2011-11-29 | |
| US61/564,602 | 2011-11-29 | ||
| US201261708709P | 2012-10-02 | 2012-10-02 | |
| US61/708,709 | 2012-10-02 | ||
| US201261730316P | 2012-11-27 | 2012-11-27 | |
| US61/730,316 | 2012-11-27 | ||
| PCT/US2012/066793 WO2013082114A1 (en) | 2011-11-29 | 2012-11-28 | Use of p3 of bacteriophage as amyloid binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017074284A Division JP6440765B2 (ja) | 2011-11-29 | 2017-04-04 | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505823A JP2015505823A (ja) | 2015-02-26 |
| JP2015505823A5 true JP2015505823A5 (enExample) | 2015-12-03 |
| JP6220344B2 JP6220344B2 (ja) | 2017-10-25 |
Family
ID=47326403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543617A Active JP6220344B2 (ja) | 2011-11-29 | 2012-11-28 | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
| JP2017074284A Active JP6440765B2 (ja) | 2011-11-29 | 2017-04-04 | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017074284A Active JP6440765B2 (ja) | 2011-11-29 | 2017-04-04 | アミロイド結合剤としてのバクテリオファージのｐ３の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9493515B2 (enExample) |
| EP (1) | EP2785364B1 (enExample) |
| JP (2) | JP6220344B2 (enExample) |
| KR (1) | KR20140100543A (enExample) |
| CN (2) | CN104093414A (enExample) |
| AU (1) | AU2012346056B2 (enExample) |
| BR (1) | BR112014013086A2 (enExample) |
| CA (1) | CA2857539C (enExample) |
| EA (2) | EA029602B1 (enExample) |
| IL (1) | IL232867B (enExample) |
| IN (1) | IN2014CN04587A (enExample) |
| MX (1) | MX362175B (enExample) |
| PH (1) | PH12014501200B1 (enExample) |
| SG (2) | SG11201402425TA (enExample) |
| WO (1) | WO2013082114A1 (enExample) |
| ZA (1) | ZA201403863B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| US9988444B2 (en) * | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
| ES2751378T3 (es) * | 2015-11-25 | 2020-03-31 | Lilly Co Eli | Vectores fagos de presentación y procedimientos de uso |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| RU2740573C1 (ru) * | 2017-07-14 | 2021-01-15 | Гсе Холдинг Аб | Электронный измеритель для контроля баллона со сжатым газом, и соответствующие способы |
| US11692017B2 (en) | 2018-06-15 | 2023-07-04 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
| KR20250110352A (ko) | 2022-12-02 | 2025-07-18 | 알제온, 인크. | 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| KR20030082962A (ko) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) |
| CA2496133A1 (en) | 2002-08-20 | 2004-03-04 | Sungene Gmbh & Co. Kgaa | Method for the production of ketocarotinoids in flower petals on plants |
| DE10238846A1 (de) * | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| JP5096169B2 (ja) | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| JP5419131B2 (ja) * | 2005-12-12 | 2014-02-19 | エーシー イミューン ソシエテ アノニム | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 |
| AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) * | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) * | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| CN101553567A (zh) | 2006-07-21 | 2009-10-07 | 台拉维夫大学拉莫特 | 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 |
| KR101485202B1 (ko) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| US20110092445A1 (en) * | 2008-07-25 | 2011-04-21 | Abbott Laboratories | Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses |
| EP2356231A2 (en) * | 2008-09-26 | 2011-08-17 | Wyeth LLC | Compatible display vector systems |
| AU2009316326A1 (en) * | 2008-11-24 | 2010-05-27 | Ramot At Tel-Aviv University Ltd. | Method for treating Parkinson' s disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| JP2014509514A (ja) | 2011-03-11 | 2014-04-21 | ラモット アット テルアヴィブ ユニヴァーシティ リミテッド | 神経変性タウオパシーを治療するための方法 |
| US8856364B2 (en) | 2011-03-11 | 2014-10-07 | Google Inc. | Conducting opportunistic network updates on a mobile device |
| EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
-
2012
- 2012-11-28 EP EP12799008.3A patent/EP2785364B1/en active Active
- 2012-11-28 WO PCT/US2012/066793 patent/WO2013082114A1/en not_active Ceased
- 2012-11-28 CN CN201280066659.6A patent/CN104093414A/zh active Pending
- 2012-11-28 MX MX2014006337A patent/MX362175B/es active IP Right Grant
- 2012-11-28 CN CN202210423575.9A patent/CN114748605A/zh active Pending
- 2012-11-28 SG SG11201402425TA patent/SG11201402425TA/en unknown
- 2012-11-28 AU AU2012346056A patent/AU2012346056B2/en active Active
- 2012-11-28 KR KR1020147017548A patent/KR20140100543A/ko not_active Ceased
- 2012-11-28 EA EA201491063A patent/EA029602B1/ru unknown
- 2012-11-28 JP JP2014543617A patent/JP6220344B2/ja active Active
- 2012-11-28 SG SG10201709849TA patent/SG10201709849TA/en unknown
- 2012-11-28 BR BR112014013086-8A patent/BR112014013086A2/pt not_active Application Discontinuation
- 2012-11-28 CA CA2857539A patent/CA2857539C/en active Active
- 2012-11-28 EA EA201792608A patent/EA201792608A3/ru unknown
- 2012-11-28 US US14/361,157 patent/US9493515B2/en active Active
-
2014
- 2014-05-27 ZA ZA2014/03863A patent/ZA201403863B/en unknown
- 2014-05-28 PH PH12014501200A patent/PH12014501200B1/en unknown
- 2014-05-29 IL IL232867A patent/IL232867B/en active IP Right Grant
- 2014-06-18 IN IN4587CHN2014 patent/IN2014CN04587A/en unknown
-
2015
- 2015-07-13 US US14/797,724 patent/US9493516B2/en active Active
-
2016
- 2016-10-07 US US15/288,237 patent/US10151762B2/en active Active
-
2017
- 2017-04-04 JP JP2017074284A patent/JP6440765B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505823A5 (enExample) | ||
| Scheckel et al. | Prions, prionoids and protein misfolding disorders | |
| Eck et al. | Regulation of TDP-43 phosphorylation in aging and disease | |
| Moreth et al. | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? | |
| JP6283366B2 (ja) | アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用 | |
| Neff et al. | Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders | |
| Krishnan et al. | A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies | |
| Reindl et al. | Meso scale discovery-based assays for the detection of aggregated huntingtin | |
| JP6220344B2 (ja) | アミロイド結合剤としてのバクテリオファージのｐ３の使用 | |
| Moda et al. | Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice | |
| Sharma et al. | Effect of disease-associated P123H and V70M mutations on β-synuclein fibrillation | |
| Eigenbrod et al. | Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice | |
| Daude et al. | Wild‐type Shadoo proteins convert to amyloid‐like forms under native conditions | |
| Southwell et al. | Antibody therapy in neurodegenerative disease | |
| Barreca et al. | Therapeutic Trajectories in Human Prion Diseases | |
| Zaccagnini | In silico and in vitro screening of acridine and phenothiazine derivatives as anti-prion agents | |
| Redaelli et al. | Clinical features, pathophysiology and management of fatal familial insomnia | |
| Noble | Biochemical and Structural Studies of Prion Protein Misfolding | |
| RS56559B1 (sr) | Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida | |
| HK1213775B (en) | Use of p3 of bacteriophage fusion proteins as amyloid binding agents | |
| HK1197655A (en) | Use of p3 of bacteriophage as amyloid binding agents | |
| HK1197655B (en) | Use of p3 of bacteriophage as amyloid binding agents |